Rethinking the Cost-Benefit of PSA Tests

Was this Fixing U.S. Healthcare blog wrong to single out PSA as not worth its cost? This was the claim in two previous posts, including the overall most popular one, The Problem of Diminishing Marginal Benefit in Healthcare. Some new information suggests that we need to rethink that original claim. Prostate Specific Antigen Since prostate … Continue reading Rethinking the Cost-Benefit of PSA Tests

Fixing U.S. Healthcare Blog – One-Year Appraisal & Summary

Fixing U.S. Healthcare blog reached its one-year anniversary last month. That’s a good time to take stock. And it’s a good time to summarize this blog’s message - that U.S. healthcare spending far outpaces spending in other comparable OECD (Organization for Economic Cooperation & Development) countries, as shown in the masthead graphic, above, and needs to … Continue reading Fixing U.S. Healthcare Blog – One-Year Appraisal & Summary

Healthcare Reform: Where to Start?

Fixing U.S. Healthcare blog has made the case for reform that reins in spending in the whole system. But where possibly to start on such a massive undertaking?  Here are four ideas. Klein’s “Muddling incrementalism” Redefining Price’s “essential benefits” using Oregon-style cost-benefit analysis Rosenthal’s “Salami strategy” Emanuel’s “low-hanging fruit” Let’s look at each one. Idea #1:  … Continue reading Healthcare Reform: Where to Start?

Doctors Critique Oregon-Style Cost-Benefit Approach to Healthcare Reform . . . But Not So Fast!

Noted surgeon and social-medical commentator Atul Gawande MD hosted a video roundtable in 2014 entitled “Avoiding Low-Value Care.” His panel seemingly challenged the idea that low-value care can be avoided, which is the crux of the cost-benefit approach to healthcare reform. But on closer look Dr. Gawande and panel may actually, in fact, be validating … Continue reading Doctors Critique Oregon-Style Cost-Benefit Approach to Healthcare Reform . . . But Not So Fast!

Genes, Cost-Effectiveness and Healthcare Reform – Dialog with Dr. Buchanan

This is a posting of my reply to British health economist Dr. Buchanan's Comment of February 17, 2018.  The original posts are: Medicines's future? The health economics of population-wide genomic screening (October 26, 2017) Cost-Effectiveness: From Genes to Healthcare System Reform (December 17, 2017) 2 thoughts on “Cost-Effectiveness: From Genes to Healthcare System Reform” (Reply, February … Continue reading Genes, Cost-Effectiveness and Healthcare Reform – Dialog with Dr. Buchanan